
<details>
<summary>Collapsable data</summary>

## c758369e-a0e6-400e-9be9-4f5b59b0a27f-data
```pdf-annot-data
entry_type: file_header 
file_uuid4: c758369e-a0e6-400e-9be9-4f5b59b0a27f 
filename: /config/workspace/groq_test/out_link.pdf 
DOI: poop 
```


## f6d16259-eb5c-4112-8d82-cc0316556aab-data

[Link to md](#f6d16259-eb5c-4112-8d82-cc0316556aab-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: f6d16259-eb5c-4112-8d82-cc0316556aab 
highlighted_text: AQP4-IgG is highly specific for NMOSD diagnosis at any titer. In contrast, caution is needed with low-titer myelin-oligodendrocyte glycoprotein-IgG (MOG-IgG), which can be encountered with other diseases. 
annotation_text: Historically some cases diagnosed AQP4 neg NMOSD with might have been MOGAD since there is a clinical overlap. However #MOGAD can have a more varying radiological apperance. 
rect: Rect(47.5974006652832, 320.12200927734375, 365.697998046875, 345.281005859375) 
```


## 66c987c1-cdb1-48ee-ad23-59fcf823b4a9-data

[Link to md](#66c987c1-cdb1-48ee-ad23-59fcf823b4a9-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: 66c987c1-cdb1-48ee-ad23-59fcf823b4a9 
highlighted_text: Similar to most autoimmune disorders, the first step of the pathophysiological cascade is represented by an unknown mechanism of loss of self-tolerance, which oc- curs in the periphery. B cells differentiate into antibody-producing plasmablasts that secrete the pathological autoantibodies that eventually enter the CNS.13,14 Antibody production and entry into the CNS may be facilitated by high levels of a proinflamma- tory cytokine called interleukin-6 (IL-6), which increases blood–brain barrier perme- ability and promotes differentiation of B cells into plasmablasts to enhance antibody-production.15 Alternatively, CNS regions free of the blood–brain barrier, such as the area postrema, may be another route of entry, especially in AQP41N- MOSD. However, intrathecal MOG-IgG production is reported in MOGAD but not AQP41NMOSD.16–20 
annotation_text: B-cells diferentiate into plasmablasts and produce andibodies. Entry to CNS probably mediated by IL-6. Intrathecal Antibody production is seen in MOGAD but nor AQP4+NMOSD. #I-S #P-PH 
rect: Rect(51.063499450683594, 418.7070007324219, 395.3659973144531, 535.343994140625) 
```


## 506c458f-3924-45f7-b4e6-9c27e84da69e-data

[Link to md](#506c458f-3924-45f7-b4e6-9c27e84da69e-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: 506c458f-3924-45f7-b4e6-9c27e84da69e 
highlighted_text: ease course, supporting a separate pathophysiology for each. There are also impor- tant differences in demographic, clinical, radiologic, and pathologic features that resulted in the need for separate criteria for MOGAD from NMOSD. This ultimately led to the publication of separate diagnostic criteria for MOGAD in 2023 to capture these patients and no longer label them as seronegative NMOSD.1 
annotation_text: However MOGAD can have a more varying radiological apperance. The diseaseas are different in pathophysiology and more. 
rect: Rect(50.529598236083984, 219.99899291992188, 395.34698486328125, 272.406005859375) 
```


## 27ea9e75-27d4-4490-9bd1-12bda56ca36c-data

[Link to md](#27ea9e75-27d4-4490-9bd1-12bda56ca36c-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: 27ea9e75-27d4-4490-9bd1-12bda56ca36c 
highlighted_text: Biomarkers of these diseases are antibodies targeting the aquaporin-4 (AQP4) wa- ter channel on the astrocyte end-feet in AQP41NMOSD3 and myelin-oligodendrocyte glycoprotein (MOG) on the outermost myelin sheath layer in MOGAD.4 
annotation_text: #AQP4 on foot of astrocyte #MOGAD on outermost layer of myelin #P-PH  
rect: Rect(53.1974983215332, 77.530029296875, 395.3529968261719, 106.21600341796875) 
```


## b882c47d-c1ac-4af2-9e7b-e8b5be3b0c8a-data

[Link to md](#b882c47d-c1ac-4af2-9e7b-e8b5be3b0c8a-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: b882c47d-c1ac-4af2-9e7b-e8b5be3b0c8a 
highlighted_text: reach the CNS. AQP4-IgGs bind to the water channel on astrocytes at the blood–brain barrier.3 The binding between the antibody and its target activates the classical pathway of the complement cascade, with primary damage to the astrocytes through the formation of the membrane attack complex and antibody-dependent cellular cytotoxicity.13 Meanwhile, secondary products of complement activation, such as the C5a anaphylatoxin, act as a chemoattractant for granulocytes, which are locally 
annotation_text: #I-S #P-PH 
rect: Rect(53.710601806640625, 550.177978515625, 395.36199951171875, 609.7587890625) 
```


## 1d6b6c7f-9590-415e-ad77-6b958994eeaa-data

[Link to md](#1d6b6c7f-9590-415e-ad77-6b958994eeaa-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: 1d6b6c7f-9590-415e-ad77-6b958994eeaa 
highlighted_text: patients with an NMOSD phenotype were negative 
annotation_text: 
rect: Rect(111.84300231933594, 151.53799438476562, 247.58200073242188, 161.05499267578125) 
```


## 5b26cd87-810d-431a-9b91-81e75a9bfdcb-data

[Link to md](#5b26cd87-810d-431a-9b91-81e75a9bfdcb-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: 5b26cd87-810d-431a-9b91-81e75a9bfdcb 
highlighted_text: AQP41NMOSD and MOGAD are rare disorders. The estimated annual incidence of AQP41NMOSD is 0.4 to 7.3/million people6,7; it is largely unknown in MOGAD, although a few European studies estimated it at 1.6 to 3.4/million people.8,9 AQP41N- MOSD mainly affects middle-aged women (40–60 years, 9:1 female to male ratio)6,7 with a predilection for Afro-Caribbean or Asian individuals.6,7 MOGAD incidence has a biphasic behavior, with a peak of incidence in children (reported up to 3 times higher)9 and later in young adults (20–30 years).10–12 No clear sex preference or high-risk ethnicities have been identified in MOGAD thus far. 
annotation_text: Unusual diseases. #Demographics #NMOSD Mainly in adult females (more afro and asian). #MOGAD in children or young adults. 
rect: Rect(51.796600341796875, 302.94000244140625, 395.8909912109375, 388.375) 
```


## 0926c63f-c90f-4747-8988-c81d7bc67a3a-data

[Link to md](#0926c63f-c90f-4747-8988-c81d7bc67a3a-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: 0926c63f-c90f-4747-8988-c81d7bc67a3a 
highlighted_text: than healthy individuals.27 However, complement activation seems less effective with MOG-IgG than AQP4-IgG, possibly because most patients have bivalent binding MOG-IgG, which are known to be less effective in complement activation.28 In addition, MOG-IgGs were able to induce demyelination also by activating the neonatal Fc- receptor pathway, which enhanced the activation and tissue infiltration by T cells in an- imal models.29 The involvement of CD41 T cells represents one of the main differences with MS, where CD81 T cells are usually predominant on pathology samples.22 Cytokine profiling is similar in AQP41NMOSD and MOGAD but different to MS, showing upregulation of T helper 17-related and some T helper 1-related molecules.30 Differences and similarities in AQP41NMOSD and MOGAD pathophysiology are summarized in Table 1 and graphically shown in Fig. 1. 
annotation_text: #I-S #P-PH  
rect: Rect(34.063499450683594, 274.8210144042969, 378.27099609375, 392.343994140625) 
```


## d56fded4-530e-487f-9e7b-cf146a5cdf7b-data

[Link to md](#d56fded4-530e-487f-9e7b-cf146a5cdf7b-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: d56fded4-530e-487f-9e7b-cf146a5cdf7b 
highlighted_text: ened by eye movements, and dyschromatopsia. At disease onset, it is the most common presentation in adult MOGAD (50%–65%)14 and relatively com- mon in AQP41NMOSD (35%).31 It can occur in isolation, in association with myelitis, or in the context of acute disseminated encephalomyelitis (ADEM).1,2 In contrast to MS, bilateral simultaneous involvement of the optic nerves is com- mon in both AQP41NMOSD (17%–82%)32,33 and MOGAD (50%–84%).33,34 Vi- sual loss at nadir is usually severe with a median visual acuity of hand movement in AQP41NMOSD and between hand movements and count fingers in MOGAD.35,36 Clues suggesting a diagnosis of MOGAD may be the presence of eye pain before the onset of visual loss (often mistaken for headache, especially in children)37 and evidence of optic disc edema at fundoscopy (86%–90%)11,36 that is often moderate to severe and sometimes accompanied by peripapillary hemorrhages.36 At follow-up, recovery is usually complete or almost complete 
annotation_text: #APQ4 and #MOGAD can have bilateral #ON as opposed to #MS . MOGAD shows better #recovery than AQP4 after optic neuritis and #LETM  
rect: Rect(55.695499420166016, 473.47198486328125, 379.2349853515625, 611.7996826171875) 
```


## 5c2126c5-d300-414d-8940-090b6d221d08-data

[Link to md](#5c2126c5-d300-414d-8940-090b6d221d08-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: 5c2126c5-d300-414d-8940-090b6d221d08 
highlighted_text: According to the most recent hypothesis, in the CNS the binding between MOG-IgG and myelin may lead to increased local production of IL-6 and B-cell activating factor (BAFF), with recruitment of CD41 T cells and macrophages that will ultimately damage neurons and oligodendrocytes.14 Complement may also contribute to MOGAD patho- physiology, as supported by preclinical models,25 evidence of complement deposition with antibody-dependent cellular phagocytosis on pathology samples22,23,26 and higher activation of both the classic and alternative complement pathways in patients than healthy individuals.27 However, complement activation seems less effective with 
annotation_text: #I-S #P-PH  
rect: Rect(32.529598236083984, 198.114990234375, 377.8429870605469, 283.406005859375) 
```


## 9283a5b4-a10a-48cb-a0bc-1bce6e8b5254-data

[Link to md](#9283a5b4-a10a-48cb-a0bc-1bce6e8b5254-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: 9283a5b4-a10a-48cb-a0bc-1bce6e8b5254 
highlighted_text: Table 1 Differences and similarities in AQP4DNMOSD and MOGAD pathophysiology 
annotation_text: #table-title #I-S #P-PH  
rect: Rect(60.364498138427734, 57.5159912109375, 334.35198974609375, 75.15997314453125) 
```


## 9e1a8676-2b9a-4333-903f-e457df77cc31-data

[Link to md](#9e1a8676-2b9a-4333-903f-e457df77cc31-md)
```pdf-annot-data
entry_type: rectangle 
annot_uuid4: 9e1a8676-2b9a-4333-903f-e457df77cc31 
img_filename: out_link-img1.jpeg 
annotation_text: Table 1 Differences and similarities in AQP4DNMOSD and MOGAD pathophysiology #table-sq #I-S #P-PH 
highlighted_text: Table 1 Differences and similarities in AQP4DNMOSD and MOGAD pathophysiology AQP4DNMOSD MOGAD Targets Antigen AQP4 MOG Cell Astrocyte Oligodendrocyte Site of antibody production Periphery Yes Yes CNS No Yes Cytokines IL-6 Yes Yes IL-10 Yes Yes IL-17a Yes Yes G-CSF Yes Yes TNF-alfa Yes Yes BAFF/APRIL Yes Yes Effectors of damage Complement Yes Yes, but less prominent Cell infiltrates Granulocytes CD41T cells, macrophages/microglia Outcomes Neuronal loss Yes Yes, but less severe Astrocytic damage Yes No Oligodendrocyte damage Not prominent Yes Demyelination Yes Yes Damage Biomarkers Neurofilament light chain High (during attacks) High (during attacks) GFAP High Normal Myelin basic protein Normal High Abbreviations: APRIL, a proliferation-inducing ligand; AQP4, aquaporin-4; AQP41NMOSD, aquaporin-4-IgG positive neuromyelitis optica spectrum disorder; BAFF, B-cell activating factor; CD4, cluster of differentiation 4; G-CSF, granulocytes colony-stimulating factor; GFAP, glial fibrillary acidic protein; IL, interleukin; MOG, myelin oligodendrocyte glycoprotein; MOGAD, myelin oligo- dendrocyte glycoprotein antibody-associated disease; TNF-alfa, tumor necrosis factor-alfa. 
rect: Rect(50.47809982299805, 49.9530029296875, 405.6969909667969, 470.07598876953125) 
```


## 3a499da3-17fb-451b-a947-5ce8486d6631-data

[Link to md](#3a499da3-17fb-451b-a947-5ce8486d6631-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: 3a499da3-17fb-451b-a947-5ce8486d6631 
highlighted_text: Yes, but less prominent 
annotation_text: Both classic and alternative pathway are triggered in MOGAD including Neonatal Fc but activation is less effective because of double binding antibodies #I-S #P-PH 
rect: Rect(258.9960021972656, 261.6400146484375, 344.4800109863281, 269.9049987792969) 
```


## d0e13eb8-cde8-46aa-821b-234b2d67ab04-data

[Link to md](#d0e13eb8-cde8-46aa-821b-234b2d67ab04-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: d0e13eb8-cde8-46aa-821b-234b2d67ab04 
highlighted_text: Fig. 1. AQP4DNMOSD and MOGAD pathogenesis. AQP41NMOSD: 1. IL-6 promotes the dif- ferentiation of B cells into AQP4-IgG secreting plasmablasts; 2. AQP4-IgGs reach the blood stream and cross the blood–brain barrier; 3. AQP4-IgGs bind to AQP4 on astrocytes and acti- vate the complement cascade through the classical pathway leading to astrocyte damage; 4. The release of anaphylatoxins after complement activation recruit granulocytes, which will ultimately damage neurons and eventually, although not primarily, oligodendrocytes (5). MOGAD: 1. IL-6 promotes the differentiation of B cells into MOG-IgG secreting plasmablasts; 2. MOG-IgGs reach the blood stream and cross the blood–brain barrier but recent evidence suggest they might also be produced intrathecally; 3. MOG-IgGs bind to MOG on oligoden- drocytes and activate the complement cascade through the classical pathway leading to oly- godendrocyte damage; 4. Local inflammation recruits T cells and monocytes/macrophages; and 5. MOG-IgGs recycling in the blood stream seems to contribute to the persistence of the mechanism of damage. Figure created with Biorender.com. Abbreviations: AQP4, 
annotation_text: Figure 1 pathogenesis of AQP4 NMOSD and MOGAD #Gobitar #P-PH #MOGAD #AQP4  #Figure-title #Figure-text #I-S  
rect: Rect(35.65620040893555, 270.1719970703125, 377.77099609375, 396.17901611328125) 
```


## cf60270a-3920-4288-a20b-1cad8a063d63-data

[Link to md](#cf60270a-3920-4288-a20b-1cad8a063d63-md)
```pdf-annot-data
entry_type: rectangle 
annot_uuid4: cf60270a-3920-4288-a20b-1cad8a063d63 
img_filename: out_link-img2.jpeg 
annotation_text: Figure 1 #Figure-sq #I-S #P-PH  
highlighted_text: Fig. 1. AQP4DNMOSD and MOGAD pathogenesis. AQP41NMOSD: 1. IL-6 promotes the dif- ferentiation of B cells into AQP4-IgG secreting plasmablasts; 2. AQP4-IgGs reach the blood stream and cross the blood–brain barrier; 3. AQP4-IgGs bind to AQP4 on astrocytes and acti- vate the complement cascade through the classical pathway leading to astrocyte damage; 4. The release of anaphylatoxins after complement activation recruit granulocytes, which will ultimately damage neurons and eventually, although not primarily, oligodendrocytes (5). MOGAD: 1. IL-6 promotes the differentiation of B cells into MOG-IgG secreting plasmablasts; 2. MOG-IgGs reach the blood stream and cross the blood–brain barrier but recent evidence suggest they might also be produced intrathecally; 3. MOG-IgGs bind to MOG on oligoden- drocytes and activate the complement cascade through the classical pathway leading to oly- godendrocyte damage; 4. Local inflammation recruits T cells and monocytes/macrophages; and 5. MOG-IgGs recycling in the blood stream seems to contribute to the persistence of the mechanism of damage. Figure created with Biorender.com. Abbreviations: AQP4, aquaporin-4; AQP41NMOSD, aquaporin-4-IgG positive neuromyelitis optica spectrum disor- der; IL-6, interleukin-6; MOG, myelin oligodendrocyte glycoprotein; MOGAD, myelin oligo- dendrocyte glycoprotein antibody-associated disease. 
rect: Rect(36.813899993896484, 49.69000244140625, 381.5220031738281, 429.87200927734375) 
```


## 4e795527-60cf-4514-9dfc-4a7e775b2aff-data

[Link to md](#4e795527-60cf-4514-9dfc-4a7e775b2aff-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: 4e795527-60cf-4514-9dfc-4a7e775b2aff 
highlighted_text: AQP41NMOSD, the area postrema syndrome, characterized by intractable vomiting or hiccups for days to several weeks, is the most frequent manifestation of brainstem involvement (16%–60% of patients).1,44 It is usually associated with 
annotation_text: 
rect: Rect(73.57759857177734, 115.90997314453125, 395.2969970703125, 144.61300659179688) 
```


## ea5c92fd-1e3e-4afc-ac38-f765f35249bb-data

[Link to md](#ea5c92fd-1e3e-4afc-ac38-f765f35249bb-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: ea5c92fd-1e3e-4afc-ac38-f765f35249bb 
highlighted_text: sented by ataxia (45%) or diplopia (26%).44 Attacks of isolated facial numbness and diplopia and trigeminal neuralgia are all much more common in MS than AQP41NMOSD or MOGAD. 
annotation_text: 
rect: Rect(73.52629852294922, 181.67401123046875, 395.3479919433594, 210.5150146484375) 
```


## 42a2a468-2289-4e65-9062-58153692e162-data

[Link to md](#42a2a468-2289-4e65-9062-58153692e162-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: 42a2a468-2289-4e65-9062-58153692e162 
highlighted_text: vere in both AQP41NMOSD and MOGAD. In both cases long-segments of inflammation (ie, T2-hyperintensity or gadolinium enhancement involving more than half the distance from the orbit to the chiasm) are common.1,2,57 However, 
annotation_text: Long-segment bilateral optic neurits #ddx-MOGAD-NMO-MS 
rect: Rect(73.57849884033203, 583.0588989257812, 395.3590087890625, 611.7619018554688) 
```


## f6081cd3-80ef-43e3-b254-3fa8421768a7-data

[Link to md](#f6081cd3-80ef-43e3-b254-3fa8421768a7-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: f6081cd3-80ef-43e3-b254-3fa8421768a7 
highlighted_text: Finally, patients with MOGAD may present with cerebral cortical encephalitis, a recently described phenotype characterized by clinical manifestations (ie, head- ache [79%], seizures [68%], encephalopathy [63%], and fever [42%])54 and typical T2-FLAIR cortical hyperintensity with corresponding leptomeningeal or cortical gadolinium enhancement.54,55 It is observed in almost 7% of all patients but is more common in children (13.5%) than in adults (3.6%).54 Cerebral cortical encephalitis often precedes other short-term MOGAD attacks. Radiological ab- normalities resolve in more than 90% of patients54 and can occasionally improve without acute immunotherapy.56 Major MRI Features 
annotation_text: 14% of children and 4% of adults show #FLAMES, cerebral cortical encephalitis, #ddx-MOGAD-NMO-MS for PRES. Causing siezures, headache and fever Leptomeningeal enhancement 
rect: Rect(53.11709976196289, 389.9070129394531, 395.36199951171875, 503.406005859375) 
```


## 7c882099-1ae5-4f66-ae39-51f36a3f1905-data

[Link to md](#7c882099-1ae5-4f66-ae39-51f36a3f1905-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: 7c882099-1ae5-4f66-ae39-51f36a3f1905 
highlighted_text: In MOGAD, ADEM represents the most common presenting manifestation in pediatric patients (20%–60%), especially in those aged younger than 12 years.2,14 It is defined by the concomitant presence of polyfocal CNS symptoms, unex- plained encephalopathy, and large poorly demarcated lesions in the gray and white matter at MRI.50 Severe encephalopathy or status epilepticus can lead to inability to protect the airway and the need for mechanical ventilation.41 Despite the potential severity of the acute phase, recovery is usually good although def- icits in cognition have been reported.51–53 
annotation_text: In #MOGAD #ADEM in white and grey matter is the most common manifestation especially in younger patients. #Recovery is usually good with exceptions 
rect: Rect(70.67630004882812, 302.2030029296875, 395.90301513671875, 385.70599365234375) 
```


## c3a82108-bc04-4aed-b9fd-67259874bb40-data

[Link to md](#c3a82108-bc04-4aed-b9fd-67259874bb40-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: c3a82108-bc04-4aed-b9fd-67259874bb40 
highlighted_text: Approximately 3% of patients with AQP41NMOSD may present with symptoms of diencephalic involvement (eg, narcolepsy, inappropriate antidiuretic hormone secretion syndrome, hyperphagia, thermic homeostasis dysregulation, and dysfunction of the hypothalamus–hypophysis axis).46,47 Other cerebral manifes- tations, including encephalopathy, ADEM, posterior-reversible encephalopathy, and seizures have been reported as well but are rare.48,49 
annotation_text: #AQP4 #Klinik very seldom show diencephalic or hypothalamic pituitary axis symptoms are rare (3%). Kramper, encefalopathy are rare.  
rect: Rect(70.6614990234375, 236.43899536132812, 395.3760070800781, 298.06201171875) 
```


## acfd51eb-a558-4e2c-968d-83c8d7d22ddc-data

[Link to md](#acfd51eb-a558-4e2c-968d-83c8d7d22ddc-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: acfd51eb-a558-4e2c-968d-83c8d7d22ddc 
highlighted_text: spinal cord lesion.45 In MOGAD, brainstem or cerebellar symptoms usually occur in the context of polyfocal cerebral involvement or ADEM, and are mainly repre- sented by ataxia (45%) or diplopia (26%).44 Attacks of isolated facial numbness 
annotation_text: 
rect: Rect(73.26969909667969, 159.7340087890625, 395.3479919433594, 188.4739990234375) 
```


## b9223842-b069-443c-be76-07fd6f0a9cc9-data

[Link to md](#b9223842-b069-443c-be76-07fd6f0a9cc9-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: b9223842-b069-443c-be76-07fd6f0a9cc9 
highlighted_text: frequently with MOGAD optic neuritis.58 Enhancement of the optic nerve sheath (perioptic enhancement/optic perineuritis) and extension to the orbital fat can also be observed in 50% of MOGAD-related optic neuritis36 and may help discriminate from MS.59 In both disorders asymptomatic enhancement may be 
annotation_text: #ddx-MOGAD-NMO-MS 
rect: Rect(55.70949935913086, 110.4110107421875, 377.7650146484375, 150.09100341796875) 
```


## 27dad52d-851f-496f-bfcf-2134f515fdc7-data

[Link to md](#27dad52d-851f-496f-bfcf-2134f515fdc7-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: 27dad52d-851f-496f-bfcf-2134f515fdc7 
highlighted_text: Approximately 85% of patients with AQP41NMOSD and 70% of patients with MOGAD with acute myelitis demonstrate longitudinally extensive spinal cord T2-lesions,39 which by definition extend over at least 3 vertebral segments on 
annotation_text: longitudinaly extensive >3 vertebra in 85% AQP4 och 70% MOGAD #LETM 
rect: Rect(53.529598236083984, 241.93899536132812, 377.76800537109375, 272.406005859375) 
```


## 40fd9b54-3471-43d3-9514-8aae9077a21a-data

[Link to md](#40fd9b54-3471-43d3-9514-8aae9077a21a-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: 40fd9b54-3471-43d3-9514-8aae9077a21a 
highlighted_text: times with optic nerve head swelling visible on MRI)2 and are commonly posteri- orly located involving the chiasm and the optic tracts in AQP41NMOSD.1,33 
annotation_text: #ddx-MOGAD-NMO-MS  
rect: Rect(56.00210189819336, 66.5880126953125, 377.7619934082031, 84.29302978515625) 
```


## 44cfab68-c8c3-412d-af80-cae1ada5a578-data

[Link to md](#44cfab68-c8c3-412d-af80-cae1ada5a578-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: 44cfab68-c8c3-412d-af80-cae1ada5a578 
highlighted_text: the anterior portion of the optic nerves in MOGAD (some- 
annotation_text: 
rect: Rect(161.22300720214844, 52.89202880859375, 348.7090148925781, 62.40997314453125) 
```


## f655168c-573a-44fc-9c6a-a2d2af63cedd-data

[Link to md](#f655168c-573a-44fc-9c6a-a2d2af63cedd-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: f655168c-573a-44fc-9c6a-a2d2af63cedd 
highlighted_text: mation.60,61 Chronic atrophy of the optic nerve or optic disc occurs in 12% to 83% of AQP41NMOSD,57,62 and can be clinically observed in MOGAD. Exam- 
annotation_text: 
rect: Rect(56.00279998779297, 176.17498779296875, 377.7340087890625, 193.8800048828125) 
```


## 7735172f-d208-4be0-b104-141a6198895e-data

[Link to md](#7735172f-d208-4be0-b104-141a6198895e-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: 7735172f-d208-4be0-b104-141a6198895e 
highlighted_text: discriminate from MS.59 In both disorders asymptomatic enhancement may be observed at the site of prior optic neuritis in approximately 20% of patients, 
annotation_text: #residual #Gd #MOGAD #NMO #ON 
rect: Rect(56.00239944458008, 140.54000854492188, 378.9590148925781, 161.05499267578125) 
```


## 700cf140-48cb-4162-9ff9-a0cb55ffef09-data

[Link to md](#700cf140-48cb-4162-9ff9-a0cb55ffef09-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: 700cf140-48cb-4162-9ff9-a0cb55ffef09 
highlighted_text: sagittal T2-weighted images.2,46 By contrast, longitudinally-extensive lesions in MS myelitis occur in less than 1%, although occasionally coalescence of multiple short lesions can artifactually appear longitudinally-extensive, and hazy longitu- dinally-extensive T2-hyperintensity can be sometimes encountered in chronic MS .64 T2-lesions are more likely to be solitary in AQP41NMOSD and multiple MOGAD.39 
annotation_text: ovanligt med #LETM hos MS även om lesioner kan konfluera eller utsträckta signalförändringar kan ses #ddx-MOGAD-NMO-MS 
rect: Rect(71.79660034179688, 396.3699951171875, 395.3630065917969, 448.375) 
```


## 2fe0fdbd-ee43-4ffd-acfa-a465f9203af9-data

[Link to md](#2fe0fdbd-ee43-4ffd-acfa-a465f9203af9-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: 2fe0fdbd-ee43-4ffd-acfa-a465f9203af9 
highlighted_text: fashion (H-sign) is more frequent in MOGAD than AQP41NMOSD.39 Marked central canal T2-hyperintensity may occur with AQP41NMOSD and MOGAD but is rare in MS and this signal change usually resolves in follow-up.70 It may reflect a potential 
annotation_text: Centralkanalen kan vidgas eller visa signalförändringar i MOGAD och AQP4 men inte MS #ddx-MOGAD-NMO-MS #LETM 
rect: Rect(51.796600341796875, 544.3389892578125, 395.364990234375, 574.375) 
```


## 6f14df03-e258-4903-9a3a-4a86f7998472-data

[Link to md](#6f14df03-e258-4903-9a3a-4a86f7998472-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: 6f14df03-e258-4903-9a3a-4a86f7998472 
highlighted_text: MS .64 T2-lesions are more likely to be solitary in AQP41NMOSD and multiple in MOGAD.39 Acute gadolinium enhancement (elongated ring-like, patchy) is almost invariably present in AQP41NMOSD but less frequent and more faint in MOGAD39,65,66; leptomeningeal enhancement can be observed in both dis- eases.65,67 To note, around 10% of acute myelitis in MOGAD initially have a normal MRI, which will usually reveal spinal cord abnormalities after a median delay of 6 days.68 
annotation_text: AQP4 myelit oftare multifokal, oftare och tydligare kontrastuppladdande än MOGAD. Båda kan ha leptomeningeal uppladdning. Myelit hos MOGAD kan dyka upp med delay. #ddx-MOGAD-NMO-MS #LETM 
rect: Rect(71.52960205078125, 440.1940002441406, 395.364013671875, 514.406005859375) 
```


## a7407ba5-a3e9-4943-bff8-ed140e48f675-data

[Link to md](#a7407ba5-a3e9-4943-bff8-ed140e48f675-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: a7407ba5-a3e9-4943-bff8-ed140e48f675 
highlighted_text: matter,2,69 although T2-hyperintensity restricted to the gray matter in an H-shaped fashion (H-sign) is more frequent in MOGAD than AQP41NMOSD.39 Marked central 
annotation_text: Både AQP4 och MOGAD har ofta centrala lesioner men att det håller sig till grå eller är H-format är vanligare i MOGAD #LETM #Pattern #ddx-MOGAD-NMO-MS 
rect: Rect(50.796600341796875, 533.3399658203125, 395.2900085449219, 552.375) 
```


## 62121534-6f59-46b7-a02d-034e3deffb38-data

[Link to md](#62121534-6f59-46b7-a02d-034e3deffb38-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: 62121534-6f59-46b7-a02d-034e3deffb38 
highlighted_text: Fig. 3. Optic neuritis in patients with MOGAD, AQP4DNMOSD, and MS. 
annotation_text: #Figure-title Figure 3 
rect: Rect(53.25149917602539, 266.9490051269531, 335.9389953613281, 275.7640075683594) 
```


## c0f6c91a-4b9a-4f30-918e-8c7254579d9b-data

[Link to md](#c0f6c91a-4b9a-4f30-918e-8c7254579d9b-md)
```pdf-annot-data
entry_type: rectangle 
annot_uuid4: c0f6c91a-4b9a-4f30-918e-8c7254579d9b 
img_filename: out_link-img3.jpeg 
annotation_text: Fig. 3. Optic neuritis in patients with MOGAD, AQP4, and MS. #ddx-MOGAD-NMO-MS #Figure-sq 
highlighted_text: Fig. 3. Optic neuritis in patients with MOGAD, AQP4DNMOSD, and MS. Top row shows schematic representation of the optic nerve during the acute phase, while follow-up imag- ing is displayed in the bottom row. All images are shown in axial view. MOGAD: Bilateral anterior optic neuritis with accompanying optic disc edema extending more than 50% of optic nerve length bilaterally with optic nerve sheaths and perioptic fat involvement (A) and minimal residual optic nerve atrophy (B). AQP41NMOSD: Bilateral optic neuritis involving the chiasm (C) with residual atrophy (D). MS: Unilateral short right optic neuritis (E) with residual focal atrophy (F). (Used with permission of Mayo Foundation for Medical Education and Research, all rights reserved.) Abbreviations: AQP41NMOSD, aquaporin-4- IgG positive neuromyelitis optica spectrum disorder; Gd, postcontrast T1-weighted images; MOGAD, myelin oligodendrocyte glycoprotein antibody-associated disease; MS, multiple sclerosis. 
rect: Rect(47.58760070800781, 44.96002197265625, 409.3760070800781, 387.5660095214844) 
```


## e5adf9d9-4fdb-4917-91fe-3f9658f5b970-data

[Link to md](#e5adf9d9-4fdb-4917-91fe-3f9658f5b970-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: e5adf9d9-4fdb-4917-91fe-3f9658f5b970 
highlighted_text: Other than the ependymal enhancement, also cloud-like, nodular, and leptomenin- geal enhancement were considered typical of AQP41NMOSD. However, more recent investigations suggest that cloud-like and nodular enhancement may be encountered with a similar frequency also in MOGAD and MS,78,81 whereas the leptomeningeal enhancement is much more common in MOGAD (46% of cerebral attacks) and can actually help discriminate from AQP41NMOSD (7%) and MS (4%).78 Persistent enhancement over 3 months is rare in all these disorders.78 
annotation_text: #cloud like and #nodular uppladdning ses i alla tre. Leptomeningeal enhancement vanligare i MOGAD 46% vs 7% i AQP4 och 4% i mS #REF #study (vilket uppladdningsmönster menar de?) e det foci? #GD  
rect: Rect(34.063499450683594, 504.93701171875, 377.77398681640625, 577.3438110351562) 
```


## b219e414-2cd1-4e3e-834f-1d711d392431-data

[Link to md](#b219e414-2cd1-4e3e-834f-1d711d392431-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: b219e414-2cd1-4e3e-834f-1d711d392431 
highlighted_text: The severity of chronic atrophy is proportional to the number of myelitis in AQP41N- MOSD and MOGAD,74 is mainly lesional rather than diffuse, and long segments of at- rophy can be a clue to AQP41NMOSD diagnosis.38,69 
annotation_text: Vanligare i AQP4 eller ses även i MOGAD frekvent? 
rect: Rect(33.796600341796875, 88.52801513671875, 377.78900146484375, 118.375) 
```


## aa894400-8e73-405e-9fe5-65fa7728ed83-data

[Link to md](#aa894400-8e73-405e-9fe5-65fa7728ed83-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: aa894400-8e73-405e-9fe5-65fa7728ed83 
highlighted_text: Brain imaging: Brain lesions are observed in up to 80% of patients with AQP41N- MOSD.75 MRI findings have been extensively analyzed and classified in 2015, with the definition of typical and nonspecific lesions.46 Typical lesions are usually observed at periependymal level,46 following regions of high AQP4 expression.76 Among them, periependymal lesions along the lateral ventricles are the most common (12%– 40%),46 especially in the course of cerebral attacks.77 Corresponding pencil-thin linear ependymal enhancement is typical of AQP41NMOSD and is neither found in MOGAD nor found in MS.78 
annotation_text: signalförändringar nära ependym (vanligast vid sidoventriklar) är typiskt för NMOSD.  ptencil thin periependymal linjär uppladdning ses bara på #AQP4 #pattern #Gd #ddx-MOGAD-NMO-MS 
rect: Rect(34.063499450683594, 143.29299926757812, 377.7969970703125, 226.343994140625) 
```


## 513f326d-aa31-4acc-ae78-5ba75f4dbbd7-data

[Link to md](#513f326d-aa31-4acc-ae78-5ba75f4dbbd7-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: 513f326d-aa31-4acc-ae78-5ba75f4dbbd7 
highlighted_text: During the acute phase, lesions may demonstrate typical patterns of heterogeneous appearance (marbled pattern) or homogeneous involvement of the splenium (arch bridge pattern), which may help diagnosis.46 Of note, callosal lesions can also be 
annotation_text: marbled pattern (inhomogen lesion), arch bridge pattern (splenium) #study typiska utseenden för #AQP4 #pattern 
rect: Rect(32.529598236083984, 230.99700927734375, 377.7380065917969, 261.406005859375) 
```


## 578c0c94-1eeb-4ce3-9d9b-52a7beb21b25-data

[Link to md](#578c0c94-1eeb-4ce3-9d9b-52a7beb21b25-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: 578c0c94-1eeb-4ce3-9d9b-52a7beb21b25 
highlighted_text: observed in patients with MOGAD at a similar frequency but their size rarely exceeds 2.5 cm (11%) and the extracallosal brain involvement is common (55%).77 Callosal le- 
annotation_text: #MOGAD kan också ha splenum lesioner men de är oftast <2.5cm #pattern 
rect: Rect(33.529598236083984, 263.8789978027344, 377.760009765625, 283.406005859375) 
```


## 1cbbcad5-95d2-4a7d-99f0-c76ce9c0b245-data

[Link to md](#1cbbcad5-95d2-4a7d-99f0-c76ce9c0b245-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: 1cbbcad5-95d2-4a7d-99f0-c76ce9c0b245 
highlighted_text: of the midbrain) that may be asymptomatic. Diencephalic lesions favor AQP41N- MOSD over MS, although rarely encountered (6% of patients with AQP41NMOSD).75 
annotation_text: Diencefaliska lesioner sägs här tala för AQP4 men de ses ju även på MS (thalamiska lesioner på 7t) #central-grey #BG #ddx-MOGAD-NMO-MS #Jack-Handey 
rect: Rect(33.796600341796875, 351.5260009765625, 381.2030029296875, 370.375) 
```


## 46d9c72b-3dc4-4e3e-94b2-3f6ef9f86124-data

[Link to md](#46d9c72b-3dc4-4e3e-94b2-3f6ef9f86124-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: 46d9c72b-3dc4-4e3e-94b2-3f6ef9f86124 
highlighted_text: are also relatively frequent (7%–46% of patients with AQP41NMOSD), and those in the dorsal medulla can involve the area postrema causing the hallmark clinical syn- drome with intractable nausea, vomiting and hiccups.46 Other brain lesions considered 
annotation_text: akvedukt, 4e ventrikel, area postrema #pattern #AQP4 
rect: Rect(33.796600341796875, 384.4079895019531, 377.7929992675781, 414.375) 
```


## 7a461e31-88bf-4e30-ad65-dde7468e67a4-data

[Link to md](#7a461e31-88bf-4e30-ad65-dde7468e67a4-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: 7a461e31-88bf-4e30-ad65-dde7468e67a4 
highlighted_text: the evidence of spinal cord lesions with areas of T2-hyperintensity at least equal to the cerebrospinal fluid (brighter spotty lesions), which tend to be more extensive than just an enlarged central canal and are more common in AQP41NMOSD.71–73 
annotation_text: AQP4 myelit kan ha t2 signal som är lika eller högre än CSF #ddx-MOGAD-NMO-MS #LETM 
rect: Rect(33.796600341796875, 55.64599609375, 377.7510070800781, 75.375) 
```


## 25139440-ba95-4276-b118-3aa3120f69e6-data

[Link to md](#25139440-ba95-4276-b118-3aa3120f69e6-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: 25139440-ba95-4276-b118-3aa3120f69e6 
highlighted_text: and large hemispheric lesions in the white matter (ie, with maximum transverse diam- eter of >3 cm, often spindle-like or with a radial shape). Similar lesions have also been reported in patients with MOGAD.80 Tumefactive lesions ( 2 cm) are more frequent in MOGAD than AQP41NMOSD (22% vs 5%).81 
annotation_text: #AQP4 (har även setts i MOGAD) kan ha stora radierande signalförändringar i vit substans. #spilled-ink medan tumefaktiva (>2cm) lesioner är vanligare på MOGAD överlag #pattern #ddx-MOGAD-NMO-MS 
rect: Rect(33.529598236083984, 428.23199462890625, 377.7919921875, 469.406005859375) 
```


## ce5c7ad1-022d-412e-a691-8a81f3b562a6-data

[Link to md](#ce5c7ad1-022d-412e-a691-8a81f3b562a6-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: ce5c7ad1-022d-412e-a691-8a81f3b562a6 
highlighted_text: Brain lesions in this disease are usually poorly demarcated (fluffy),84 in line with what is observed in patients with ADEM,50 of which conversely 50% test positive for MOG- IgG.85 Transient faint T1-hypointensity can occur in the acute phase of MOGAD but MS.81 
annotation_text: Fluffighet ses i MOGAD lesioner liksom i ADEM. 50% av #ADEM är #MOGAD #pattern #fluffy 
rect: Rect(33.796600341796875, 119.32501220703125, 377.7829895019531, 151.375) 
```


## ee635f59-5ee5-4ded-adb6-58a2a29f10b6-data

[Link to md](#ee635f59-5ee5-4ded-adb6-58a2a29f10b6-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: ee635f59-5ee5-4ded-adb6-58a2a29f10b6 
highlighted_text: the peripheral white matter (I, axial view). showing a ring-pattern of enhancement 
annotation_text: ring mönster kan ses även i #MS #S-chord #pattern  
rect: Rect(168.06399536132812, 543.656005859375, 333.9360046386719, 555.3438110351562) 
```


## cc29a777-a7e9-420f-ae62-5a36ec272c46-data

[Link to md](#cc29a777-a7e9-420f-ae62-5a36ec272c46-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: cc29a777-a7e9-420f-ae62-5a36ec272c46 
highlighted_text: After the acute event, brain T2-lesion resolution is very common in MOGAD (60%– 79%),2,81,92–94 can occasionally be observed in AQP41NMOSD (14%–27%),44,81,93,95 and is very rare in MS (0%–17%).44,81,92,93 Similar findings are observed in the spinal 
annotation_text: lesioner kan gå tillbaka, vanligare i MOGAD än MS #lesion-resolution #ref #study #repair 
rect: Rect(33.529598236083984, 358.66900634765625, 381.4700012207031, 378.406005859375) 
```


## 07e9dc1e-848a-4a5c-b490-94b08cba2d66-data

[Link to md](#07e9dc1e-848a-4a5c-b490-94b08cba2d66-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: 07e9dc1e-848a-4a5c-b490-94b08cba2d66 
highlighted_text: and, rarely, leukodystrophy-like patterns.63,82,83 Among all these locations, lesions in the deep gray matter63,82 and large lesions in the middle cerebellar peduncles44 are the most characteristic and more common in MOGAD than in AQP41NMOSD. Diffuse 
annotation_text: bla #ADEM liknande mönster är vanliga vid #MOGAD men det finns en stor variation. Även kortikala, subkortikala och juxtakortikala lesioner ses i MOGAD #kortikal 
rect: Rect(33.330501556396484, 66.5880126953125, 377.7380065917969, 95.31201171875) 
```


## 5bc46f78-4b1e-40a3-952a-cc13bc0d430a-data

[Link to md](#5bc46f78-4b1e-40a3-952a-cc13bc0d430a-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: 5bc46f78-4b1e-40a3-952a-cc13bc0d430a 
highlighted_text: the most characteristic and more common in MOGAD than in AQP41NMOSD. Diffuse involvement of the pons and/or adjacent to the fourth ventricle (anterior location) may also favor MOGAD over AQP41NMOSD, although not confirmed in all studies.44,82 (fluffy),84 
annotation_text: Även #MOGAD kan visa lesioner i pons eller vid 4e ventrikel #patterm #BS #4e 
rect: Rect(33.796600341796875, 88.52801513671875, 377.77801513671875, 118.375) 
```


## 49ed0f94-b70e-4d49-be81-e9cf669e7e16-data

[Link to md](#49ed0f94-b70e-4d49-be81-e9cf669e7e16-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: 49ed0f94-b70e-4d49-be81-e9cf669e7e16 
highlighted_text: Fig. 5. Myelitis in patients with MOGAD, AQP4DNMOSD, and MS. Top 
annotation_text: #Figure-title Schematisk figur ryggmärgslesioner. #LETM#ddx-MOGAD-NMO-MS 
rect: Rect(52.330501556396484, 457.68798828125, 313.66900634765625, 468.31201171875) 
```


## 09087955-0437-4a67-8cb1-7bb0b81b8acf-data

[Link to md](#09087955-0437-4a67-8cb1-7bb0b81b8acf-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: 09087955-0437-4a67-8cb1-7bb0b81b8acf 
highlighted_text: and another lesion in the conus (A, 
annotation_text: #conus myelit kan tala för #MOGAD #LETM #pattern 
rect: Rect(248.3300018310547, 497.68701171875, 356.6700134277344, 508.31201171875) 
```


## fae083ff-d994-4720-bce0-cc5ecafa42c6-data

[Link to md](#fae083ff-d994-4720-bce0-cc5ecafa42c6-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: fae083ff-d994-4720-bce0-cc5ecafa42c6 
highlighted_text: extensive myelitis with a T2-lesion involving with elongated ring enhancement (E). The 
annotation_text: ringuppladdning kan tala för AQP4 #Gd #pattern #ring #LETM 
rect: Rect(206.06399536132812, 556.6561889648438, 337.9360046386719, 568.3438110351562) 
```


## 4a228a20-c6c0-4167-a80d-f85cc97e6cd2-data

[Link to md](#4a228a20-c6c0-4167-a80d-f85cc97e6cd2-md)
```pdf-annot-data
entry_type: rectangle 
annot_uuid4: 4a228a20-c6c0-4167-a80d-f85cc97e6cd2 
img_filename: out_link-img4.jpeg 
annotation_text: #Figure-sq #LETM #ddx-MOGAD-NMO-MS figure 5 
highlighted_text: Fig. 5. Myelitis in patients with MOGAD, AQP4DNMOSD, and MS. Top row shows spinal cord findings during the acute phase (T2-weighted images and postcontrast T1-weighted images), whereas follow-up imaging is displayed in the bottom row (T2-weighted images). MOGAD: Longitudinally extensive myelitis with a linear T2-lesion appearance involving the lower cervical and upper to middle thoracic cord and another lesion in the conus (A, sagittal view). There is associated H-sign with the T2-lesion restricted to gray matter (C, axial view). Minimum linear enhancement and leptomeningeal enhancement of the conus (B, sagittal view). The T2-lesion completely resolved on T2-weighted images at follow-up (J, sagittal view and L, axial view), with no evident atrophy. Gadolinium enhancement resolved (K). AQP41NMOSD: Longitudinally extensive myelitis with a T2-lesion involving the cervical and thoracic cord (D, sagittal view) with elongated ring enhancement (E). The T2-lesion is centrally located in both the gray and the white matter (F, axial view). At follow-up, the lesion is smaller on T2-weighted images (M, sagittal and O, axial view) although still present. Gadolinium enhancement resolved (N). MS: Multiple focal short spinal cord T2-lesions (G, sagittal view) located in the peripheral white matter (I, axial view). One lesion shows 
rect: Rect(54.21310043334961, 48.74200439453125, 402.6409912109375, 613.9702758789062) 
```


## 41830d84-8ffa-4e4a-b616-818ff45c8e29-data

[Link to md](#41830d84-8ffa-4e4a-b616-818ff45c8e29-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: 41830d84-8ffa-4e4a-b616-818ff45c8e29 
highlighted_text: Large reductions and progressive fragmentation is typical in AQP41NMOSD, although complete resolution is rare,92,93,96 and persistence of T2-lesions is the rule in MS.92,93 
annotation_text: AQP4 spinala lesioner går delvis tillbaka medan MS är mer stationär #resolution #repair 
rect: Rect(34.063499450683594, 176.17498779296875, 377.7460021972656, 204.343994140625) 
```


## 1df5e3d6-94e0-49a7-91d2-65422772a0bc-data

[Link to md](#1df5e3d6-94e0-49a7-91d2-65422772a0bc-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: 1df5e3d6-94e0-49a7-91d2-65422772a0bc 
highlighted_text: lesions has been commonly used in MS clinical trials as a surrogate end-point.97 In AQP41NMOSD and MOGAD, the frequency of new or enlarging asymptomatic T2- lesions is rare and estimated between 3% and 13%98–101 and between 3% and 14%,100–102 respectively. This has implications for clinical practice because surveil- lance MRIs are generally not recommended in AQP41NMOSD or MOGAD. Moreover, it has implications for upcoming clinical trials in these disorders because this will be a 
annotation_text: i motsats till MS har AQP4 och MOGAD sällan asymptomatiska lesioner vilket gör att upppföljningsradiologi inte rekommenderas normalt  (till skillnad mot MS)  
rect: Rect(33.796600341796875, 263.8789978027344, 377.7850036621094, 316.375) 
```


## d5a8168c-455d-4432-8336-d22a03a01c88-data

[Link to md](#d5a8168c-455d-4432-8336-d22a03a01c88-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: d5a8168c-455d-4432-8336-d22a03a01c88 
highlighted_text: (F, arrows) with accompanying fourth ventricle ex vacuo enlargement. Bilateral fluffy T2- lesions of the thalami (C, arrows) in a patient with prominent leptomeningeal enhancement (zoom-in picture, postcontrast T1-weighted sequence) undergoing complete resolution at follow-up (G). Patient with cerebral cortical encephalitis showing an extensive cortical T2- 
annotation_text: Fluffig lesion i thalamus och kontrastuppladdning #MOGAD #Pattern #fluffy #BG #BS #4e 
rect: Rect(51.063499450683594, 291.0350036621094, 395.3110046386719, 319.343994140625) 
```


## 96015c36-f210-417e-bf4e-adbc96eb4326-data

[Link to md](#96015c36-f210-417e-bf4e-adbc96eb4326-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: 96015c36-f210-417e-bf4e-adbc96eb4326 
highlighted_text: view. Poorly defined (ie, fluffy) T2-lesions in the entire medulla and cerebellum completely resolving at follow-up imaging (E). Bilateral fluffy T2-lesions in the 
annotation_text: Fluffiga lesioner i hjärnstam och cerebellum, kan även ha runt 4e ventrikel #MOGAD #ddx-MOGAD-NMO-MS #fluffy 
rect: Rect(117.06400299072266, 257.656005859375, 397.9360046386719, 269.343994140625) 
```


## f8abdc5e-e5ae-4971-a7ad-1b4f8f89b45a-data

[Link to md](#f8abdc5e-e5ae-4971-a7ad-1b4f8f89b45a-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: f8abdc5e-e5ae-4971-a7ad-1b4f8f89b45a 
highlighted_text: ease controls.107,115,116 The positive predictive value of MOG-IgG increases when or- dered in high probability situations and with higher antibody titers.115 MOG-IgG is still (z98%–99%), 
annotation_text: MOG-IgG kan finnas i mindre grad även hos friska #Lab #I-S #MOGAD 
rect: Rect(33.796600341796875, 505.3909912109375, 377.7439880371094, 524.375) 
```


## 68ff57ed-6e66-4fe7-9635-42eaf0c38967-data

[Link to md](#68ff57ed-6e66-4fe7-9635-42eaf0c38967-md)
```pdf-annot-data
entry_type: rectangle 
annot_uuid4: 68ff57ed-6e66-4fe7-9635-42eaf0c38967 
img_filename: out_link-img5.jpeg 
annotation_text: #Figure-sq #MOGAD Figure 7  
highlighted_text: Fig. 7. Brain lesions in patients with MOGAD. Top row shows brain findings during the acute phase, while follow-up imaging is displayed in the bottom row. Images are all shown on axial view. T2-lesion involving the entire medulla (A), completely resolving at follow-up (F). Bilateral fluffy T2-lesions in the middle cerebellar peduncles (B) resolved at follow-up (G). Bilateral fluffy T2-lesions of the thalami and additional lesions in the white matter (C) undergoing complete resolution at follow-up (H). Cerebral cortical encephalitis with an extensive cortical T2-lesion (D) accompanied by leptomeningeal enhancement (E). Both cortical lesion and enhancement completely resolved at follow-up (I, J). (Used with permis- sion of Mayo Foundation for Medical Education and Research, all rights reserved.) Abbrevi- ations: FLAIR, fluid-attenuated inversion recovery; Gd, postcontrast T1-weighted images; MOGAD, myelin oligodendrocyte glycoprotein antibody-associated disease. 
rect: Rect(31.032800674438477, 41.54400634765625, 396.1310119628906, 356.19000244140625) 
```


## 155054c3-c50c-4788-897d-07176b17adf4-data

[Link to md](#155054c3-c50c-4788-897d-07176b17adf4-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: 155054c3-c50c-4788-897d-07176b17adf4 
highlighted_text: Fig. 7. Brain lesions in patients with MOGAD. 
annotation_text: #Figure-title Figure 7 #MOGAD schematisk bild även runt #4e 
rect: Rect(35.676700592041016, 240.4169921875, 215.36199951171875, 249.23199462890625) 
```


## a6917d30-83a7-4df2-8c66-727536ff122a-data

[Link to md](#a6917d30-83a7-4df2-8c66-727536ff122a-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: a6917d30-83a7-4df2-8c66-727536ff122a 
highlighted_text: reduced in size but still visible at follow-up (I, arrow). Multiple small nonspecific T2-lesions in the subcortical white matter (E, arrows), persisting unchanged at follow-up 
annotation_text: AQP4 NMOSD subkortikala lesioner har mer "ospecifikt" utseende. 
rect: Rect(51.063499450683594, 323.5199890136719, 395.2510070800781, 341.343994140625) 
```


## 962fb20d-6272-49d0-9d45-b052138a7a84-data

[Link to md](#962fb20d-6272-49d0-9d45-b052138a7a84-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: 962fb20d-6272-49d0-9d45-b052138a7a84 
highlighted_text: CSF positivity can be observed in isolation in 3% to 29%,17–20,118–120 and in suspicious cases negative for MOG-IgG in serum, CSF MOG-IgG testing should be undertaken. Patients with evidence of intrathecal synthesis of MOG-IgG or CSF MOG-IgG positivity 
annotation_text: 3-29% av MOGAD har antikroppar som enbart detekteras i CSF 
rect: Rect(50.796600341796875, 450.739013671875, 398.2030029296875, 470.375) 
```


## c49e7066-c6c6-46e9-8850-055387abf3fc-data

[Link to md](#c49e7066-c6c6-46e9-8850-055387abf3fc-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: c49e7066-c6c6-46e9-8850-055387abf3fc 
highlighted_text: nostic criteria. CSF usually reveals pleocytosis in more than 50% of patients with MOGAD (median 31–40 cells/mL)121,122 and AQP41NMOSD (median 19 cells/mL)123 but rarely in MS. Cells are usually predominantly lymphocytes121–123 although also (MOGAD),121,122 MOGAD),121–123 
annotation_text: CSF pleocytos talar för AQP4 o MOGAD men ej MS 
rect: Rect(51.796600341796875, 549.38330078125, 395.88800048828125, 579.375) 
```


## 8b498b08-f23e-42c6-8de9-5b1a3f2c9898-data

[Link to md](#8b498b08-f23e-42c6-8de9-5b1a3f2c9898-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: 8b498b08-f23e-42c6-8de9-5b1a3f2c9898 
highlighted_text: in the area postrema (A, 
annotation_text: area postrema kräkning är typiskt fynd #AQP4 #Pattern #area-postrema  
rect: Rect(210.3300018310547, 260.68798828125, 285.6700134277344, 271.31298828125) 
```


## dac210c8-9e11-4150-8bd9-a132203fed38-data

[Link to md](#dac210c8-9e11-4150-8bd9-a132203fed38-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: dac210c8-9e11-4150-8bd9-a132203fed38 
highlighted_text: pons (G). Peri- 
annotation_text: AQP4 lesioner periependymalt med linear enhancement 
rect: Rect(374.0639953613281, 279.656005859375, 394.9360046386719, 291.343994140625) 
```


## 2036f8d3-5b45-4720-b3a3-8ec91d8e711f-data

[Link to md](#2036f8d3-5b45-4720-b3a3-8ec91d8e711f-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: 2036f8d3-5b45-4720-b3a3-8ec91d8e711f 
highlighted_text: postcontrast T1-weighted sequence), persisting at follow-up (H, arrow). the splenium of the corpus callosum in another patient (D, arrow), significantly 
annotation_text: Splenium lesion i APQ4 
rect: Rect(104.06400299072266, 309.656005859375, 349.9360046386719, 321.343994140625) 
```


## 7f5ece32-3e64-4af7-9570-a1d8b830470f-data

[Link to md](#7f5ece32-3e64-4af7-9570-a1d8b830470f-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: 7f5ece32-3e64-4af7-9570-a1d8b830470f 
highlighted_text: 9. Brain lesions in patients with AQP4DNMOSD. Top 
annotation_text: #Figure-title Fig 9 Schematisk bild i #AQP4. Bla lesion #cortikospinal-tract vilket är vanligare i AQP4 #non-specific prickar #pencil #ependymal #spilled-ink inte med #Pattern #ddx-MOGAD-NMO-MS 
rect: Rect(60.063499450683594, 239.656005859375, 240.93600463867188, 251.343994140625) 
```


## f148ac5e-731c-43d3-bf1d-b5b379e7ac34-data

[Link to md](#f148ac5e-731c-43d3-bf1d-b5b379e7ac34-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: f148ac5e-731c-43d3-bf1d-b5b379e7ac34 
highlighted_text: Approximately 2% to 3% of patients with AQP41NMOSD can have coexistent myasthenia gravis.126,127 Although AQP41NMOSD diagnosis usually follows that of myasthenia,128 antiacetylcholine receptor antibody in serum should be checked in case of compatible clinical manifestations. Rarely MOG-IgG was also found coexisting with AQP4-IgG and in most cases is likely related to its background rate being found in 1% to 2% of disease controls. Most patients with dual AQP4-IgG and MOG-IgG pos- 
annotation_text: 2-3% av AQP4 har samtidig #myasthenia gravis #study (brukar redan vara känt vid AQP4 diagnos) - Antiacetylcholine antikroppar bör kollas om symptomen kan likna. #de-va-som-fan 
rect: Rect(34.063499450683594, 418.7070007324219, 377.7860107421875, 481.343994140625) 
```


## 803eac40-ac46-4f4c-83b2-13cf843cdf4d-data

[Link to md](#803eac40-ac46-4f4c-83b2-13cf843cdf4d-md)
```pdf-annot-data
entry_type: rectangle 
annot_uuid4: 803eac40-ac46-4f4c-83b2-13cf843cdf4d 
img_filename: out_link-img6.jpeg 
annotation_text: Fig. 9. Brain lesions in patients with #AQP4#Figure-sq 
highlighted_text: Fig. 9. Brain lesions in patients with AQP4DNMOSD. Top row shows brain findings during the acute phase, whereas follow-up imaging is displayed in the bottom row. Images are all shown on axial view. T2-lesion in the area postrema (A) smaller but still present at follow-up (F). Posterior T2-lesion abutting to the fourth ventricle (B) smaller but still present at follow- up (G). T2-lesion in the corticospinal tract and splenium of the corpus callosum (C) smaller but still present at follow-up (H). Multiple small nonspecific T2-lesions in the subcortical white matter (D), persisting unchanged at follow-up (I). Additional interval T2-lesions are observed as well (I). The presence of linear ependymal enhancement (E), resolving at follow-up (J) is typical of AQP41NMOSD. (Used with permission of Mayo Foundation for Medical Education and Research, all rights reserved.) Abbreviations: AQP41NMOSD, aquaporin-4-IgG positive neuromyelitis optica spectrum disorder; FLAIR, fluid-attenuated inversion recovery; Gd, postcontrast T1-weighted images. 
rect: Rect(25.1466007232666, 39.02099609375, 385.6199951171875, 367.1210021972656) 
```


## 90592d81-5a8a-4f42-a522-6521cb5bd834-data

[Link to md](#90592d81-5a8a-4f42-a522-6521cb5bd834-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: 90592d81-5a8a-4f42-a522-6521cb5bd834 
highlighted_text: lights several differences. First, for AQP41NMOSD diagnosis, but not MOGAD, there is a seronegative or unknown antibody status category.1 Because MOG-IgG is found NMOSD,130,131 
annotation_text: MOGAD i motsats till NMO har ingen variant utan känd antikropp 
rect: Rect(51.529598236083984, 408.843017578125, 395.34600830078125, 428.406005859375) 
```


## adfeba4e-5742-46f2-8d43-e29465c1da40-data

[Link to md](#adfeba4e-5742-46f2-8d43-e29465c1da40-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: adfeba4e-5742-46f2-8d43-e29465c1da40 
highlighted_text: Acute treatment in both AQP41NMOSD and MOGAD is similar to MS. It mainly in- cludes intravenous steroids and plasma exchange although occasionally, intravenous 
annotation_text: Steroids plasma exchange #study och #ivIg ges #behandling 
rect: Rect(51.063499450683594, 594.05859375, 395.35699462890625, 613.3436889648438) 
```


## 3be82e83-5dee-4ee5-87d9-878d799ac074-data

[Link to md](#3be82e83-5dee-4ee5-87d9-878d799ac074-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: 3be82e83-5dee-4ee5-87d9-878d799ac074 
highlighted_text: immunoglobulin (IVIg) is also used. The details are summarized in Table 5. There is ev- idence that early treatment (ie, <7 day-delay from symptoms onset) reduces the likeli- hood of residual deficits in both AQP41NMOSD and MOGAD.132 Moreover, the use of 
annotation_text: Tidig behandling av AQP4 och MOGAD minskar sannolikheten för kvarstående symtom (<7 dagar, dvs barn med neurologi bör avbildas inom enstaka dagar. max) #Subakut #early #treatment 
rect: Rect(33.796600341796875, 390.1969909667969, 377.7929992675781, 420.375) 
```


## 39f4e561-6734-43af-83a1-65b18f98ad14-data

[Link to md](#39f4e561-6734-43af-83a1-65b18f98ad14-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: 39f4e561-6734-43af-83a1-65b18f98ad14 
highlighted_text: many months have sometimes been used to prevent early relapses but the majority of patients will not have an early relapse and prolonged steroids has a large side effect children.10,137,138 
annotation_text: Antagligen inte klokt att ge långa steroidbehanlingar i #MOGAD så de sällan får tidig relaps - Dvs man vill veta om det är MOGAD vs AQP4 för att inte ge detta. MOGAD kan få längre behandling efter 2 eller fler attacker #avoid #unnecessary #steroid #treatment 
rect: Rect(33.796600341796875, 488.89300537109375, 377.7489929199219, 508.375) 
```


## 275aa0e6-94ab-424b-9896-8c67b87a467a-data

[Link to md](#275aa0e6-94ab-424b-9896-8c67b87a467a-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: 275aa0e6-94ab-424b-9896-8c67b87a467a 
highlighted_text: Because AQP4-IgG positive patients with AQP41NMOSD at first clinical attack are at high risk of relapses in the first year (70%) and disability worsening is strongly associ- ated with acute attacks, all newly diagnosed patients should undergo a chronic treat- ment aimed to prevent attacks.103 In contrast with AQP41NMOSD, approximately 
annotation_text: 70% av AQP4 NMOSD får relapse inom 1 år med ökande handikap, de bör behandlas långvarigt #treatment #relapse #disability 
rect: Rect(33.529598236083984, 572.1182861328125, 377.79901123046875, 613.4061889648438) 
```


## a9e4b61c-efbb-4ce9-9811-47a37cdd3e8e-data

[Link to md](#a9e4b61c-efbb-4ce9-9811-47a37cdd3e8e-md)
```pdf-annot-data
entry_type: rectangle 
annot_uuid4: a9e4b61c-efbb-4ce9-9811-47a37cdd3e8e 
img_filename: out_link-img7.jpeg 
annotation_text: #ddx-MOGAD-NMO-MS #Table 2 #Table-sq #Pattern 
highlighted_text: Table 2 Imaging findings in AQP4DNMOSD, MOGAD, and MS AQP4DNMOSD MOGAD MS Optic nerve Bilateral involvement 11 11 - Longitudinally extensive lesions (>50% length of optic nerve) 11 11 - Location Posterior with chiasm Anterior Anterior/middle Optic nerve enhancement 111 111 111 Optic nerve sheath enhancement - 11 - Perioptic fat enhancement - 11 - Spinal cord Multiple lesions - 11 111 Longitudinally extensive lesions 111 111 - Location (axial) Central Central Peripheral Gray matter involved 111 111 1 White matter involved 11 1 111 Location (sagittal) Cervico-thoracic Cervico-thoracic Cervico-thoracic Conus involved 1 11 1 Parenchymal enhancement Lens-shape, heterogeneous Faint, ill-defined Ring, nodular Leptomeningeal enhancement 1 11 - Brain Shape Along white matter tracts Poorly demarcated Ovoid Cortical lesions - 1 11 Juxtacortical lesions - 11 111 Subcortical lesions 11 1 - Periventricular lesions Peri-3rd/4th ventricle and peri-ependymal lateral ventricles - Dawson’s fingers 
rect: Rect(42.38460159301758, 39.5479736328125, 403.6990051269531, 620.3306884765625) 
```


## dd758b30-0a4d-4f2e-aee0-e17a3d6df702-data

[Link to md](#dd758b30-0a4d-4f2e-aee0-e17a3d6df702-md)
```pdf-annot-data
entry_type: rectangle 
annot_uuid4: dd758b30-0a4d-4f2e-aee0-e17a3d6df702 
img_filename: out_link-img8.jpeg 
annotation_text: #LAB -fynd #Table 3 Oligoklonala band kan ses i 20% av #MOGAD och #AQP4 #de-va-som-fan #OCB #ddx-MOGAD-NMO-MS #Table-sq 
highlighted_text: Table 3 Recommendations and laboratory features of AQP4DNMOSD and MOGAD AQP4DNMOSD MOGAD Antibody AQP4-IgG1 MOG-IgG1 Sample Serum Yes (preferred) Yes (preferred) CSF No (isolated CSF AQP4-IgG extremely rare) Yes (z10% isolated CSF MOG-IgG) Test assay Live CBA Yes (gold standard) Yes (gold standard) Fixed CBA Yes Yes Murine tissue-based assays Intermediate sensitivity but very good specificity May have white matter staining when CSF tested but very insensitive24 ELISA Good performance but reduced sensitivity and risk of false positives at low titer vs CBAs Not recommended due to inconsistent results Quantitative results important No Yes (risk of false positives at low titer) Seroconversion important No Yes (relapse-risk) CSF findings Pleocytosis 11 11 High protein 11 11 Oligoclonal bands 1 (<20%) 1 (<20%) Note that: “-” indicates rare findings (<5%), “1” infrequent findings (5%–30%), “11” common findings (30%–69%), “111” very common findings (>570%). Abbreviations: AQP4, aquaporin-4; AQP41NMOSD, aquaporin-4-IgG positive neuromyelitis optica spectrum disorder; CBA, cell-based assay; CSF, cerebrospinal fluid; ELISA, enzyme-linked immunosorbent assay; MOG, myelin oligodendrocyte glycoprotein; MOGAD, myelin-oligodendrocyte glycoprotein antibody- associated disease. 
rect: Rect(79.80339813232422, 47.95697021484375, 370.9049987792969, 620.751220703125) 
```


## 014e0e9c-7da4-4578-91e0-be449023ef39-data

[Link to md](#014e0e9c-7da4-4578-91e0-be449023ef39-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: 014e0e9c-7da4-4578-91e0-be449023ef39 
highlighted_text: Main treatment protocols in AQP4DNMOSD and MOGAD 
annotation_text: tabell för behandlingar 
rect: Rect(41.330501556396484, 73.68798828125, 251.6699981689453, 84.31298828125) 
```


## 8eef315b-b2bf-49fb-b85c-d2d6d0e0e9ef-data

[Link to md](#8eef315b-b2bf-49fb-b85c-d2d6d0e0e9ef-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: 8eef315b-b2bf-49fb-b85c-d2d6d0e0e9ef 
highlighted_text: AQP41NMOSD represents one of the few neurological disorders with tailored proven treatments available, where drugs target key elements of disease pathophys- iology, namely (1) IL-6 (satralizumab), (2) B cells and their subsets (inebilizumab and rituximab), and (3) complement (eculizumab, ravulizumab). The very high efficacy of these biologic drugs was demonstrated in phase 3 clinical trials (level 1 evidence of efficacy), although only in AQP41NMOSD. Biosimilars of rituximab are potential al- 
annotation_text: #AQP4 läkemedel med azteknamn som riktar sig mot specifika mål i immunsystemet: IL-6, B-celler, komplement #Treatment #gobitar #I-S 
rect: Rect(51.063499450683594, 99.468994140625, 395.35101318359375, 162.343994140625) 
```


## eb41f4ed-bd2c-4014-80c4-aa79d151cb9d-data

[Link to md](#eb41f4ed-bd2c-4014-80c4-aa79d151cb9d-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: eb41f4ed-bd2c-4014-80c4-aa79d151cb9d 
highlighted_text: Eculizumab 
annotation_text: riktar sig mot komplement, c5 inhiberas vilket hindrar membran komplex attacken. 94% minskad återfallsrisk. behöver vaccineras mot meningit 
rect: Rect(51.330501556396484, 286.68798828125, 104.66999816894531, 297.31298828125) 
```


## 21a4aad8-2810-4309-951b-117c7ed722b1-data

[Link to md](#21a4aad8-2810-4309-951b-117c7ed722b1-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: 21a4aad8-2810-4309-951b-117c7ed722b1 
highlighted_text: Ravulizumab 
annotation_text: liknar eculizumab, antikropp som riktar sig mot c5 
rect: Rect(51.330501556396484, 480.68701171875, 110.66999816894531, 491.31201171875) 
```


## b3d8db08-507b-4d47-a2d8-385584ded339-data

[Link to md](#b3d8db08-507b-4d47-a2d8-385584ded339-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: b3d8db08-507b-4d47-a2d8-385584ded339 
highlighted_text: Rituximab 
annotation_text: chimeric monoclonal antikropp mot cd20 på Bceller. Ingen dog, bra säkerhetsprofil 
rect: Rect(34.5974006652832, 66.718994140625, 82.40260314941406, 76.281005859375) 
```


## 2d4cdfbf-519d-4eb7-b1fc-f4a24c8d6fa9-data

[Link to md](#2d4cdfbf-519d-4eb7-b1fc-f4a24c8d6fa9-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: 2d4cdfbf-519d-4eb7-b1fc-f4a24c8d6fa9 
highlighted_text: Inebilizumab 
annotation_text: riktar sig mot cd19 som finns både på bceller men även plasmablaster och i mindre grad plasmaceller. Återfallsrisken minskade med 77% 
rect: Rect(34.330501556396484, 171.68798828125, 92.66950225830078, 182.31298828125) 
```


## 71f68c1e-61ba-46cd-a400-5dfac5231ed0-data

[Link to md](#71f68c1e-61ba-46cd-a400-5dfac5231ed0-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: 71f68c1e-61ba-46cd-a400-5dfac5231ed0 
highlighted_text: 74% to 79% in patients with AQP41NMOSD.155,156 In contrast to the other medica- tions, satralizumab administration is a subcutaneous injection, so it can be given at home. The adverse effects included upper respiratory or urinary infections and 
annotation_text: Satralizumab kan ges i hemmet.74-77% minskad relapsrisk 
rect: Rect(32.796600341796875, 451.5889892578125, 377.74200439453125, 471.375) 
```


## c508d89b-4483-4e28-9590-34ce468556c5-data

[Link to md](#c508d89b-4483-4e28-9590-34ce468556c5-md)
```pdf-annot-data
entry_type: highlight 
annot_uuid4: c508d89b-4483-4e28-9590-34ce468556c5 
highlighted_text: nance treatments. However, rituximab seems less effective in MOGAD than AQP4- IgG positive AQP41NMOSD, despite B cell depletion.162 Thus, IVIg or tocilizumab are often favored in clinical practice. Clinical trials evaluating the efficacy of rituximab 
annotation_text: Ingen level 1 evidens finns än så länge för MOGAD behandling. rituximab är inte lika effektiv som vid AQP4 hos MOGAD. IVIG eller tocilizumab används ofta i praktiken 
rect: Rect(34.063499450683594, 583.0598754882812, 377.8479919433594, 613.3436889648438) 
```

</details>



## f6d16259-eb5c-4112-8d82-cc0316556aab-md

[Link to data](#f6d16259-eb5c-4112-8d82-cc0316556aab-data)



## 66c987c1-cdb1-48ee-ad23-59fcf823b4a9-md

[Link to data](#66c987c1-cdb1-48ee-ad23-59fcf823b4a9-data)



## 506c458f-3924-45f7-b4e6-9c27e84da69e-md

[Link to data](#506c458f-3924-45f7-b4e6-9c27e84da69e-data)



## 27ea9e75-27d4-4490-9bd1-12bda56ca36c-md

[Link to data](#27ea9e75-27d4-4490-9bd1-12bda56ca36c-data)



## b882c47d-c1ac-4af2-9e7b-e8b5be3b0c8a-md

[Link to data](#b882c47d-c1ac-4af2-9e7b-e8b5be3b0c8a-data)



## 1d6b6c7f-9590-415e-ad77-6b958994eeaa-md

[Link to data](#1d6b6c7f-9590-415e-ad77-6b958994eeaa-data)



## 5b26cd87-810d-431a-9b91-81e75a9bfdcb-md

[Link to data](#5b26cd87-810d-431a-9b91-81e75a9bfdcb-data)



## 0926c63f-c90f-4747-8988-c81d7bc67a3a-md

[Link to data](#0926c63f-c90f-4747-8988-c81d7bc67a3a-data)



## d56fded4-530e-487f-9e7b-cf146a5cdf7b-md

[Link to data](#d56fded4-530e-487f-9e7b-cf146a5cdf7b-data)



## 5c2126c5-d300-414d-8940-090b6d221d08-md

[Link to data](#5c2126c5-d300-414d-8940-090b6d221d08-data)



## 9283a5b4-a10a-48cb-a0bc-1bce6e8b5254-md

[Link to data](#9283a5b4-a10a-48cb-a0bc-1bce6e8b5254-data)



## 9e1a8676-2b9a-4333-903f-e457df77cc31-md

[Link to data](#9e1a8676-2b9a-4333-903f-e457df77cc31-data)

### yay rectangle

![img](https://raw.githubusercontent.com/3cnf-f/pubdots_2/main/out_link-img1.jpeg)



## 3a499da3-17fb-451b-a947-5ce8486d6631-md

[Link to data](#3a499da3-17fb-451b-a947-5ce8486d6631-data)



## d0e13eb8-cde8-46aa-821b-234b2d67ab04-md

[Link to data](#d0e13eb8-cde8-46aa-821b-234b2d67ab04-data)



## cf60270a-3920-4288-a20b-1cad8a063d63-md

[Link to data](#cf60270a-3920-4288-a20b-1cad8a063d63-data)

### yay rectangle

![img](https://raw.githubusercontent.com/3cnf-f/pubdots_2/main/out_link-img2.jpeg)



## 4e795527-60cf-4514-9dfc-4a7e775b2aff-md

[Link to data](#4e795527-60cf-4514-9dfc-4a7e775b2aff-data)



## ea5c92fd-1e3e-4afc-ac38-f765f35249bb-md

[Link to data](#ea5c92fd-1e3e-4afc-ac38-f765f35249bb-data)



## 42a2a468-2289-4e65-9062-58153692e162-md

[Link to data](#42a2a468-2289-4e65-9062-58153692e162-data)



## f6081cd3-80ef-43e3-b254-3fa8421768a7-md

[Link to data](#f6081cd3-80ef-43e3-b254-3fa8421768a7-data)



## 7c882099-1ae5-4f66-ae39-51f36a3f1905-md

[Link to data](#7c882099-1ae5-4f66-ae39-51f36a3f1905-data)



## c3a82108-bc04-4aed-b9fd-67259874bb40-md

[Link to data](#c3a82108-bc04-4aed-b9fd-67259874bb40-data)



## acfd51eb-a558-4e2c-968d-83c8d7d22ddc-md

[Link to data](#acfd51eb-a558-4e2c-968d-83c8d7d22ddc-data)



## b9223842-b069-443c-be76-07fd6f0a9cc9-md

[Link to data](#b9223842-b069-443c-be76-07fd6f0a9cc9-data)



## 27dad52d-851f-496f-bfcf-2134f515fdc7-md

[Link to data](#27dad52d-851f-496f-bfcf-2134f515fdc7-data)



## 40fd9b54-3471-43d3-9514-8aae9077a21a-md

[Link to data](#40fd9b54-3471-43d3-9514-8aae9077a21a-data)



## 44cfab68-c8c3-412d-af80-cae1ada5a578-md

[Link to data](#44cfab68-c8c3-412d-af80-cae1ada5a578-data)



## f655168c-573a-44fc-9c6a-a2d2af63cedd-md

[Link to data](#f655168c-573a-44fc-9c6a-a2d2af63cedd-data)



## 7735172f-d208-4be0-b104-141a6198895e-md

[Link to data](#7735172f-d208-4be0-b104-141a6198895e-data)



## 700cf140-48cb-4162-9ff9-a0cb55ffef09-md

[Link to data](#700cf140-48cb-4162-9ff9-a0cb55ffef09-data)



## 2fe0fdbd-ee43-4ffd-acfa-a465f9203af9-md

[Link to data](#2fe0fdbd-ee43-4ffd-acfa-a465f9203af9-data)



## 6f14df03-e258-4903-9a3a-4a86f7998472-md

[Link to data](#6f14df03-e258-4903-9a3a-4a86f7998472-data)



## a7407ba5-a3e9-4943-bff8-ed140e48f675-md

[Link to data](#a7407ba5-a3e9-4943-bff8-ed140e48f675-data)



## 62121534-6f59-46b7-a02d-034e3deffb38-md

[Link to data](#62121534-6f59-46b7-a02d-034e3deffb38-data)



## c0f6c91a-4b9a-4f30-918e-8c7254579d9b-md

[Link to data](#c0f6c91a-4b9a-4f30-918e-8c7254579d9b-data)

### yay rectangle

![img](https://raw.githubusercontent.com/3cnf-f/pubdots_2/main/out_link-img3.jpeg)



## e5adf9d9-4fdb-4917-91fe-3f9658f5b970-md

[Link to data](#e5adf9d9-4fdb-4917-91fe-3f9658f5b970-data)



## b219e414-2cd1-4e3e-834f-1d711d392431-md

[Link to data](#b219e414-2cd1-4e3e-834f-1d711d392431-data)



## aa894400-8e73-405e-9fe5-65fa7728ed83-md

[Link to data](#aa894400-8e73-405e-9fe5-65fa7728ed83-data)



## 513f326d-aa31-4acc-ae78-5ba75f4dbbd7-md

[Link to data](#513f326d-aa31-4acc-ae78-5ba75f4dbbd7-data)



## 578c0c94-1eeb-4ce3-9d9b-52a7beb21b25-md

[Link to data](#578c0c94-1eeb-4ce3-9d9b-52a7beb21b25-data)



## 1cbbcad5-95d2-4a7d-99f0-c76ce9c0b245-md

[Link to data](#1cbbcad5-95d2-4a7d-99f0-c76ce9c0b245-data)



## 46d9c72b-3dc4-4e3e-94b2-3f6ef9f86124-md

[Link to data](#46d9c72b-3dc4-4e3e-94b2-3f6ef9f86124-data)



## 7a461e31-88bf-4e30-ad65-dde7468e67a4-md

[Link to data](#7a461e31-88bf-4e30-ad65-dde7468e67a4-data)



## 25139440-ba95-4276-b118-3aa3120f69e6-md

[Link to data](#25139440-ba95-4276-b118-3aa3120f69e6-data)



## ce5c7ad1-022d-412e-a691-8a81f3b562a6-md

[Link to data](#ce5c7ad1-022d-412e-a691-8a81f3b562a6-data)



## ee635f59-5ee5-4ded-adb6-58a2a29f10b6-md

[Link to data](#ee635f59-5ee5-4ded-adb6-58a2a29f10b6-data)



## cc29a777-a7e9-420f-ae62-5a36ec272c46-md

[Link to data](#cc29a777-a7e9-420f-ae62-5a36ec272c46-data)



## 07e9dc1e-848a-4a5c-b490-94b08cba2d66-md

[Link to data](#07e9dc1e-848a-4a5c-b490-94b08cba2d66-data)



## 5bc46f78-4b1e-40a3-952a-cc13bc0d430a-md

[Link to data](#5bc46f78-4b1e-40a3-952a-cc13bc0d430a-data)



## 49ed0f94-b70e-4d49-be81-e9cf669e7e16-md

[Link to data](#49ed0f94-b70e-4d49-be81-e9cf669e7e16-data)



## 09087955-0437-4a67-8cb1-7bb0b81b8acf-md

[Link to data](#09087955-0437-4a67-8cb1-7bb0b81b8acf-data)



## fae083ff-d994-4720-bce0-cc5ecafa42c6-md

[Link to data](#fae083ff-d994-4720-bce0-cc5ecafa42c6-data)



## 4a228a20-c6c0-4167-a80d-f85cc97e6cd2-md

[Link to data](#4a228a20-c6c0-4167-a80d-f85cc97e6cd2-data)

### yay rectangle

![img](https://raw.githubusercontent.com/3cnf-f/pubdots_2/main/out_link-img4.jpeg)



## 41830d84-8ffa-4e4a-b616-818ff45c8e29-md

[Link to data](#41830d84-8ffa-4e4a-b616-818ff45c8e29-data)



## 1df5e3d6-94e0-49a7-91d2-65422772a0bc-md

[Link to data](#1df5e3d6-94e0-49a7-91d2-65422772a0bc-data)



## d5a8168c-455d-4432-8336-d22a03a01c88-md

[Link to data](#d5a8168c-455d-4432-8336-d22a03a01c88-data)



## 96015c36-f210-417e-bf4e-adbc96eb4326-md

[Link to data](#96015c36-f210-417e-bf4e-adbc96eb4326-data)



## f8abdc5e-e5ae-4971-a7ad-1b4f8f89b45a-md

[Link to data](#f8abdc5e-e5ae-4971-a7ad-1b4f8f89b45a-data)



## 68ff57ed-6e66-4fe7-9635-42eaf0c38967-md

[Link to data](#68ff57ed-6e66-4fe7-9635-42eaf0c38967-data)

### yay rectangle

![img](https://raw.githubusercontent.com/3cnf-f/pubdots_2/main/out_link-img5.jpeg)



## 155054c3-c50c-4788-897d-07176b17adf4-md

[Link to data](#155054c3-c50c-4788-897d-07176b17adf4-data)



## a6917d30-83a7-4df2-8c66-727536ff122a-md

[Link to data](#a6917d30-83a7-4df2-8c66-727536ff122a-data)



## 962fb20d-6272-49d0-9d45-b052138a7a84-md

[Link to data](#962fb20d-6272-49d0-9d45-b052138a7a84-data)



## c49e7066-c6c6-46e9-8850-055387abf3fc-md

[Link to data](#c49e7066-c6c6-46e9-8850-055387abf3fc-data)



## 8b498b08-f23e-42c6-8de9-5b1a3f2c9898-md

[Link to data](#8b498b08-f23e-42c6-8de9-5b1a3f2c9898-data)



## dac210c8-9e11-4150-8bd9-a132203fed38-md

[Link to data](#dac210c8-9e11-4150-8bd9-a132203fed38-data)



## 2036f8d3-5b45-4720-b3a3-8ec91d8e711f-md

[Link to data](#2036f8d3-5b45-4720-b3a3-8ec91d8e711f-data)



## 7f5ece32-3e64-4af7-9570-a1d8b830470f-md

[Link to data](#7f5ece32-3e64-4af7-9570-a1d8b830470f-data)



## f148ac5e-731c-43d3-bf1d-b5b379e7ac34-md

[Link to data](#f148ac5e-731c-43d3-bf1d-b5b379e7ac34-data)



## 803eac40-ac46-4f4c-83b2-13cf843cdf4d-md

[Link to data](#803eac40-ac46-4f4c-83b2-13cf843cdf4d-data)

### yay rectangle

![img](https://raw.githubusercontent.com/3cnf-f/pubdots_2/main/out_link-img6.jpeg)



## 90592d81-5a8a-4f42-a522-6521cb5bd834-md

[Link to data](#90592d81-5a8a-4f42-a522-6521cb5bd834-data)



## adfeba4e-5742-46f2-8d43-e29465c1da40-md

[Link to data](#adfeba4e-5742-46f2-8d43-e29465c1da40-data)



## 3be82e83-5dee-4ee5-87d9-878d799ac074-md

[Link to data](#3be82e83-5dee-4ee5-87d9-878d799ac074-data)



## 39f4e561-6734-43af-83a1-65b18f98ad14-md

[Link to data](#39f4e561-6734-43af-83a1-65b18f98ad14-data)



## 275aa0e6-94ab-424b-9896-8c67b87a467a-md

[Link to data](#275aa0e6-94ab-424b-9896-8c67b87a467a-data)



## a9e4b61c-efbb-4ce9-9811-47a37cdd3e8e-md

[Link to data](#a9e4b61c-efbb-4ce9-9811-47a37cdd3e8e-data)

### yay rectangle

![img](https://raw.githubusercontent.com/3cnf-f/pubdots_2/main/out_link-img7.jpeg)



## dd758b30-0a4d-4f2e-aee0-e17a3d6df702-md

[Link to data](#dd758b30-0a4d-4f2e-aee0-e17a3d6df702-data)

### yay rectangle

![img](https://raw.githubusercontent.com/3cnf-f/pubdots_2/main/out_link-img8.jpeg)



## 014e0e9c-7da4-4578-91e0-be449023ef39-md

[Link to data](#014e0e9c-7da4-4578-91e0-be449023ef39-data)



## 8eef315b-b2bf-49fb-b85c-d2d6d0e0e9ef-md

[Link to data](#8eef315b-b2bf-49fb-b85c-d2d6d0e0e9ef-data)



## eb41f4ed-bd2c-4014-80c4-aa79d151cb9d-md

[Link to data](#eb41f4ed-bd2c-4014-80c4-aa79d151cb9d-data)



## 21a4aad8-2810-4309-951b-117c7ed722b1-md

[Link to data](#21a4aad8-2810-4309-951b-117c7ed722b1-data)



## b3d8db08-507b-4d47-a2d8-385584ded339-md

[Link to data](#b3d8db08-507b-4d47-a2d8-385584ded339-data)



## 2d4cdfbf-519d-4eb7-b1fc-f4a24c8d6fa9-md

[Link to data](#2d4cdfbf-519d-4eb7-b1fc-f4a24c8d6fa9-data)



## 71f68c1e-61ba-46cd-a400-5dfac5231ed0-md

[Link to data](#71f68c1e-61ba-46cd-a400-5dfac5231ed0-data)



## c508d89b-4483-4e28-9590-34ce468556c5-md

[Link to data](#c508d89b-4483-4e28-9590-34ce468556c5-data)

